The Europe Autoinjectors Market size was worth USD 0.83 billion in 2021 and estimated to be growing at a CAGR of 16.32%, to reach USD 1.76 billion by 2026.
Factors like an increase in the commonness of chronic diseases, increasing the biologics market, authorities of self-injection devices such as pen injectors, advanced technology, and patient compliance are propelling the market growth. The rise in the occurrence of anaphylaxis, an increase in serving to regulate the action of approving. Additionally, factors like authority for these devices such as protective syringes, prefilled syringes, and auto-disabled syringes are increasing the growth of the market. Escalating patient attentiveness, promising reimbursements, and government funding and design advancements and government funds are also the factors that propel the market.
The government authority of the expiry of biologics to drive the demand for biosimilar provides better opportunities in the market. Novel formulations of drugs and advances in drug delivery systems along with expressing approval from the government provide an opportunity for the market. Staying on top trends is essential for the decision-makers to leverage the existing opportunity.
Alternative methods such as spoken and application of drug delivery, safety concerns, and risk of infections carried out by the blood are anticipated to hamper the growth. High price and lack of awareness regarding self-medication, strict regulations and injuries connected with auto-injectors are hindering growth. Challenges that the market is facing are lack of proper action of having a skill for the usage of auto-injectors and development of auto-injectors for many drug sticky and semi-fluid consistency. An inclination for alternative drug-delivery modes such as epinephrine nasal sprays and oral diabetic agents and oral insulin are the challenges for the growth of the auto-injectors market in Europe.
This research report has been segmented & sub-segmented the market into the following categories:
Regionally, In Europe, Germany leads the market, followed by France and U.K. The market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness and favourable reimbursement policies. The existence of market key players in Germany is majorly accelerating market growth. Also, innovation in drug delivery systems, adoption of auto-injectors is growing, diabetes and cancer; favourable government policies are also fuelling the Germany Autoinjectors Market.
Europe is always an essential element in the world’s economy. In the European autoinjectors market, Germany alone will add USD 3.9 Billion in the next 5 to 6 years, and the other projected demand in the region from the Rest of the European market is USD 3.2 Billion. The European Medicines Agency surveys the safety of the people in all the countries. Due to the growing presence of diabetic patient count and increasing population, the German autoinjectors market is growing tremendously in Germany. Rising awareness of autoinjectors in the people and the adoption of sedentary lifestyles are major factors for the UK autoinjectors market to grow. Funding and the approval given by the governments for the research and development are helpful for the manufacturing of new products. Moreover, further research and advancement in technologies are attracting the major manufacturing companies, and it boosts the autoinjectors market growth in the forecast period.
Promising companies in European Autoinjectors Market profiled in this report are Mylan N.V., Pfizer, Inc., Bayer AG, Becton, Dickinson and Company, Novartis AG, Biogen Idec, Inc., Janssen North America Services, LLC, Sanofi, Unilife Corporation and Eli Lilly and Company.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Fillable Autoinjectors
5.1.3 Prefilled Autoinjectors
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Usability
5.2.1 Introduction
5.2.2 Disposable Autoinjectors
5.2.3 Reusable Autoinjectors
5.2.4 Y-o-Y Growth Analysis, By Usability
5.2.5 Market Attractiveness Analysis, By Usability
5.2.6 Market Share Analysis, By Usability
5.3 Manufacturing Design
5.3.1 Introduction
5.3.2 Standardized Autoinjectors
5.3.3 Customized Autoinjectors
5.3.4 Y-o-Y Growth Analysis, By Manufacturing Design
5.3.5 Market Attractiveness Analysis, By Manufacturing Design
5.3.6 Market Share Analysis, By Manufacturing Design
5.4 Technology
5.4.1 Introduction
5.4.2 Automated Autoinjectors
5.4.3 Manual Autoinjectors
5.4.4 Y-o-Y Growth Analysis, By Technology
5.4.5 Market Attractiveness Analysis, By Technology
5.4.6 Market Share Analysis, By Technology
5.5 Application
5.5.1 Introduction
5.5.2 Anaphylaxis
5.5.3 Multiple Sclerosis
5.5.4 Rheumatoid Arthritis
5.5.5 Y-o-Y Growth Analysis, By Application
5.5.6 Market Attractiveness Analysis, By Application
5.5.7 Market Share Analysis, By Application
5.6 Distribution Channels
5.6.1 Introduction
5.6.2 Hospitals
5.6.3 Retail
5.6.4 Online Pharmacies
5.6.5 Others
5.6.6 Y-o-Y Growth Analysis, By Distribution Channels
5.6.7 Market Attractiveness Analysis, By Distribution Channels
5.6.8 Market Share Analysis, By Distribution Channels
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Usability
6.1.3.4 By Manufacturing Design
6.1.3.5 By Technology
6.1.3.6 By Application
6.1.3.7 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Usability
6.1.4.4 By Manufacturing Design
6.1.4.5 By Technology
6.1.4.6 By Application
6.1.4.7 By Distribution Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Usability
6.1.5.4 By Manufacturing Design
6.1.5.5 By Technology
6.1.5.6 By Application
6.1.5.7 By Distribution Channels
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Mylan N.V.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer, Inc.,
8.3 Bayer AG
8.4 Becton, Dickinson and Company
8.5 Novartis AG
8.6 Biogen Idec, Inc.,
8.7 Janssen Global Services
8.8 Sanofi
8.9 Eli Lilly and Company
8.10 Unilife Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
